-  Written informed consent signed by parent(s)/legal guardians of the pediatric patient<br/>             in compliance with the local laws and regulations. In addition signed children's<br/>             assent form according to local requirements<br/><br/>          -  Male or female in- or out-patients from neonates (full term) to <17 years at the time<br/>             of randomization<br/><br/>          -  Patient weight at least 3.2 kg<br/><br/>          -  Histologically, and/or cytologically (or imaging in the case of brain tumors)<br/>             confirmed malignant disease<br/><br/>          -  Naïve or non-naïve to chemotherapy<br/><br/>          -  Scheduled and eligible to receive at least one of the moderately or highly emetogenic<br/>             chemotherapeutic agents on Study Day 1<br/><br/>          -  For patients aged ≥ 10 years to <17 years: ECOG PS ≤ 2<br/><br/>          -  For patients with known hepatic impairment: in the Investigator's opinion the<br/>             impairment should not jeopardize patient's safety during the study<br/><br/>          -  For patients with known renal impairment: in the Investigator's opinion the<br/>             impairment should not jeopardize patient's safety during the study<br/><br/>          -  For patients with known history or predisposition to cardiac abnormalities: in the<br/>             Investigator's opinion the history/predisposition should not jeopardize patient's<br/>             safety during the study<br/><br/>          -  For patients with known clinically relevant abnormal laboratory values: in the<br/>             Investigator's opinion the abnormality should not jeopardize the patient's safety<br/>             during the study<br/><br/>          -  Fertile patients (male or female) must use reliable contraceptive measures<br/><br/>          -  Female patients who have attained menarche must have a negative pregnancy test at the<br/>             screening visit (Visit 1) and at study treatment visit (Visit 2)<br/>